ASMB
NASDAQ · Biotechnology
Assembly Biosciences Inc
$20.42
+0.42 (+2.10%)
Financial Highlights (FY 2026)
Revenue
134.01M
Net Income
-11,347,616
Gross Margin
—
Profit Margin
-8.5%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 38.9% | 38.9% |
| Operating Margin | -16.8% | -143.3% | 3.5% | 3.8% |
| Profit Margin | -8.5% | -133.8% | 2.8% | 2.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 134.01M | 44.93M | 300.07M | 309.84M |
| Gross Profit | — | — | 116.85M | 120.66M |
| Operating Income | -22,460,481 | -64,397,469 | 10.55M | 11.74M |
| Net Income | -11,347,616 | -56,963,075 | 8.49M | 9.09M |
| Gross Margin | — | — | 38.9% | 38.9% |
| Operating Margin | -16.8% | -143.3% | 3.5% | 3.8% |
| Profit Margin | -8.5% | -133.8% | 2.8% | 2.9% |
| Rev Growth | — | +65.8% | +3.4% | +15.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 138.81M | 136.47M |
| Total Equity | — | — | 166.11M | 184.14M |
| D/E Ratio | — | — | 0.84 | 0.74 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -22,221,462 | -67,781,254 | 15.38M | 17.46M |
| Free Cash Flow | — | — | 12.77M | 10.54M |